Revance Therapeutics (RVNC) Tops Q4 EPS by 3c

Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.83), $0.03 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $60 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• FDA approves Padcev plus Keytruda for muscle-invasive bladder cancer
• Piper Sandler on FirstSun Capital Bancorp (FSUN): 'We expect shares to underperform on Friday'